ABCL vs BIIB: Which Stock is Better?
Side-by-side comparison of Abcellera Biologics Inc and Biogen Inc in 2026
ABCL
Abcellera Biologics Inc
$4.16
BIIB
Biogen Inc
$165.38
Key Metrics Comparison
| Metric | ABCL | BIIB | Winner |
|---|---|---|---|
| Market Cap | $1.23B | $24.26B | BIIB |
| P/E Ratio | N/A | 15.09 | BIIB |
| EPS (TTM) | $N/A | $10.96 | BIIB |
| Revenue Growth | 0.4% | 0.0% | ABCL |
| Gross Margin | -417.5% | 76.6% | BIIB |
Analyze ABCL
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ABCL or BIIB a better investment?
Comparing ABCL and BIIB: Abcellera Biologics Inc has a market cap of $1.23B while Biogen Inc has $24.26B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ABCL and BIIB?
ABCL (Abcellera Biologics Inc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ABCL or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ABCL or BIIB?
ABCL has higher revenue growth at 0.4% vs 0.0% for BIIB.
Which company is more profitable: ABCL or BIIB?
Biogen Inc (BIIB) has higher gross margins at 76.6% compared to -417.5% for ABCL.
Which is the larger company: ABCL or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $24.26B compared to $1.23B for ABCL.
Should I buy ABCL or BIIB in 2026?
Both ABCL and BIIB have investment merit. ABCL trades at $4.16 while BIIB trades at $165.38. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ABCL and BIIB stock?
Key differences: Market Cap ($1.23B vs $24.26B), P/E Ratio (N/A vs 15.1x), Revenue Growth (0.4% vs 0.0%), Gross Margin (-417.5% vs 76.6%).